Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för carmoxirole. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2011-10-25

Hypothyroidism stimulates D2 receptor-mediated breathing in response to acute hypoxia and alters D2 receptors levels in carotid bodies and brain.

Schlenker EH, Schultz HD.

Respir Physiol Neurobiol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.resp.2011.10.013

Bibliografisk träff 2004-05-01

A new synthesis of indole 5-carboxylic acids and 6-hydroxy-indole-5-carboxylic acids in the preparation of an o-hydroxylated metabolite of vilazodone.

Heinrich T, Böttcher H.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2004.01.110

Bibliografisk träff 2002-06-01

Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.

Marchese G, Ruiu S, Casti P, Bartholini F, Saba P, Gessa GL, Pani L.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/s0014-2999(02)01896-4

Bibliografisk träff 1998-09-01

Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure.

van der Ent M, van den Heuvel AF, Remme WJ.

Cardiovasc Drugs Ther · journal article · DOI 10.1023/a:1007776918751

Bibliografisk träff 1998-01-01

Dopamine: pharmacologic and therapeutic aspects.

Velasco M, Luchsinger A.

Am J Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1097/00045391-199801000-00007

Bibliografisk träff 1995-02-01

Carmoxirole inhibits platelet aggregation in vitro and ex vivo.

Kirsten R, Breidert M, Sparwasser K, Ochs JG, Hesse K, Nelson K.

Int J Clin Pharmacol Ther · clinical trial; journal article

Bibliografisk träff 1993-09-01

Erythrocyte and platelet cationic concentrations and transport systems in normal volunteers treated with carmoxirole.

Lijnen P, Petrov V, Tjandramaga T, Verbesselt R, Amery A.

Methods Find Exp Clin Pharmacol · research support, non-u.s. gov't; journal article

Bibliografisk träff 1993-01-01

Dopamine receptor modulation of noradrenaline release by carmoxirole in human cortical kidney slices.

Rump LC, Schwertfeger E, Schaible U, Schuster MJ, Frankenschmidt A, Schollmeyer P.

Eur J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/bf01428393

Bibliografisk träff 1992-09-01

Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist.

Meyer W, Bühring KU, Steiner K, Ungethüm W, Schnurr E.

Eur Heart J · clinical trial, phase ii; clinical trial; clinical trial, phase i; journal article · DOI 10.1093/eurheartj/13.suppl_d.121

Bibliografisk träff 1992-09-01

Pharmacological basis for antihypertensive therapy with a novel dopamine agonist.

Haeusler G, Lues I, Minck KO, Schelling P, Seyfried CA.

Eur Heart J · review; journal article · DOI 10.1093/eurheartj/13.suppl_d.129

Bibliografisk träff 1992-03-01

Effects of the novel dopamine DA2-receptor agonist carmoxirole (EMD 45609) on noradrenergic and purinergic neurotransmission in rat isolated kidney.

Rump LC, Wilde K, Bohmann C, Schollmeyer P.

Naunyn Schmiedebergs Arch Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/bf00168691

Bibliografisk träff 1991-06-01

Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.

Haase AF, Greiner HE, Seyfried CA.

Naunyn Schmiedebergs Arch Pharmacol · journal article · DOI 10.1007/bf00184289